Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies...

Descripción completa

Detalles Bibliográficos
Autores principales: Malmström, Rickard E., Godman, Brian B., Diogene, Eduard, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen, Ferrario, Alessandra, Finlayson, Alexander E., Fürst, Jurij, Garuoliene, Kristina, Gomes, Miguel, Gutiérrez-Ibarluzea, Iñaki, Haycox, Alan, Hviding, Krystyna, Herholz, Harald, Hoffmann, Mikael, Jan, Saira, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Langner, Irene, Lonsdale, Julie, Lööv, Sven-Äke, Malinowska, Kamila, McCullagh, Laura, Paterson, Ken, Markovic-Pekovic, Vanda, Martin, Andrew, Piessnegger, Jutta, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Tulunay, Cankat, Tomek, Dominik, Vončina, Luka, Vlahovic-Palcevski, Vera, Wale, Janet, Wilcock, Michael, Wladysiuk, Magdalena, van Woerkom, Menno, Zara, Corrine, Gustafsson, Lars L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653065/
https://www.ncbi.nlm.nih.gov/pubmed/23717279
http://dx.doi.org/10.3389/fphar.2013.00039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653065/
https://www.ncbi.nlm.nih.gov/pubmed/23717279
http://dx.doi.org/10.3389/fphar.2013.00039

Ejemplares similares